chf5074
Small moleculeexperimental
Clinical trial activity
7 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2009 (NCT00954252)
Timeline
Indications
Studied for
Mechanism of action
- Presenilin 1MODULATOR
PSEN1 modulator
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 1-(3',4'-dichloro-2-fluoro(1,1'-biphenyl)-4-yl)cyclopropanecarboxylic acid
- chf5074
- chf5074
- chf5074
- chf 5074
- chf 5074
- chf 5074
- chf-5074
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01723670 | Phase 2 | Dec 1, 2012 | Cerespir, The Memory Enhancement Center of America, Inc. |
| NCT01602393 | Phase 2 | May 1, 2012 | Chiesi, The Memory Enhancement Center of America, Inc., University of Milan |
| NCT01421056 | Phase 2 | Jul 1, 2011 | Chiesi, The Memory Enhancement Center of America, Inc., University of Milan |
| NCT01303744 | Phase 2 | Mar 1, 2011 | Cerespir, The Memory Enhancement Center of America, Inc., University of Milan |
| NCT01258452 | Phase 1 | Feb 1, 2011 | Cerespir, Iberica Co. Ltd. |
| NCT01203384 | Phase 1 | Sep 1, 2010 | Cerespir, Iberica Co. Ltd. |
| NCT00954252 | Phase 1 | Oct 1, 2009 | Cerespir, Iberica Co. Ltd. |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cerespir | For profit | 5 | 5 | 2 | 2009 |
| The Memory Enhancement Center of America, Inc. | Academic/Hospital | 4 | 0 | 1 | 2011 |
| Iberica Co. Ltd. | For profit | 3 | 0 | 1 | 2009 |
| University of Milan | Academic/Hospital | 3 | 0 | 1 | 2011 |
| Chiesi | For profit | 2 | 2 | 1 | 2011 |
5 organizations
Page 1 / 1